Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 26

1.

Performance of the cobas HPV Test for the Triage of Atypical Squamous Cells of Undetermined Significance Cytology in Cervical Specimens Collected in SurePath.

Tewari D, Novak-Weekley S, Hong C, Aslam S, Behrens CM.

Am J Clin Pathol. 2017 Nov 2;148(5):450-457. doi: 10.1093/ajcp/aqx091.

PMID:
29045515
2.

Examining word association networks: A cross-country comparison of women's perceptions of HPV testing and vaccination.

Schmid BC, Carlson J, Rezniczek GA, Wyllie J, Jaaback K, Vencovsky F.

PLoS One. 2017 Oct 5;12(10):e0185669. doi: 10.1371/journal.pone.0185669. eCollection 2017.

3.

The risk of preterm birth and growth restriction in pregnancy after cancer.

Hartnett KP, Ward KC, Kramer MR, Lash TL, Mertens AC, Spencer JB, Fothergill A, Howards PP.

Int J Cancer. 2017 Dec 1;141(11):2187-2196. doi: 10.1002/ijc.30914. Epub 2017 Aug 24.

PMID:
28836277
4.

How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country.

Velentzis LS, Caruana M, Simms KT, Lew JB, Shi JF, Saville M, Smith MA, Lord SJ, Tan J, Bateson D, Quinn M, Canfell K.

Int J Cancer. 2017 Dec 15;141(12):2410-2422. doi: 10.1002/ijc.30926. Epub 2017 Oct 5.

PMID:
28801947
5.

Cervical cancer in Africa, Latin America and the Caribbean and Asia: Regional inequalities and changing trends.

Vaccarella S, Laversanne M, Ferlay J, Bray F.

Int J Cancer. 2017 Nov 15;141(10):1997-2001. doi: 10.1002/ijc.30901. Epub 2017 Aug 10.

PMID:
28734013
6.

Psychometric Testing of the Pap Smear Belief Questionnaire: Measuring Women's Attitudes and Beliefs Toward Cervical Cancer Screening.

Ackerson K, Stines Doane L.

J Nurs Meas. 2017 Apr 1;25(1):77-89. doi: 10.1891/1061-3749.25.1.77.

PMID:
28395701
7.

Comparison of efficacy of meperidine and fentanyl in terms of pain management and quality of life in patients with cervical cancer receiving intracavitary brachytherapy: a double-blind, randomized controlled trial.

Thanthong S, Rojthamarat S, Worasawate W, Vichitvejpaisal P, Nantajit D, Ieumwananontachai N.

Support Care Cancer. 2017 Aug;25(8):2531-2537. doi: 10.1007/s00520-017-3662-3. Epub 2017 Mar 18.

PMID:
28315010
8.

The impact of community health educators on uptake of cervical and breast cancer prevention services in Nigeria.

Chigbu CO, Onyebuchi AK, Onyeka TC, Odugu BU, Dim CC.

Int J Gynaecol Obstet. 2017 Jun;137(3):319-324. doi: 10.1002/ijgo.12150. Epub 2017 Mar 31.

PMID:
28295268
9.

Cervical cancer prevention in upper middle-income countries.

Rodríguez AC, Salmerón J.

Prev Med. 2017 May;98:36-38. doi: 10.1016/j.ypmed.2016.12.032. Epub 2017 Feb 6.

PMID:
28279261
10.

Viral E6 is overexpressed via high viral load in invasive cervical cancer with episomal HPV16.

Hong D, Liu J, Hu Y, Lu X, Li B, Li Y, Hu D, Lu W, Xie X, Cheng X.

BMC Cancer. 2017 Feb 15;17(1):136. doi: 10.1186/s12885-017-3124-9.

11.

Spatial variations in cervical cancer prevention in Colombia: Geographical differences and associated socio-demographic factors.

Bermedo-Carrasco S, Waldner C, Peña-Sánchez JN, Szafron M.

Spat Spatiotemporal Epidemiol. 2016 Nov;19:78-90. doi: 10.1016/j.sste.2016.07.002. Epub 2016 Aug 3.

PMID:
27839583
12.

The prevalence of HPV types in women with CIN 2-3 or cervical cancer in Haifa district, Israel.

Siegler E, Sharir K, Lavie O, Saked-Misan P, Machulki L, Auslender R, Segev Y.

Minerva Ginecol. 2017 Jun;69(3):211-217. doi: 10.23736/S0026-4784.16.03980-0. Epub 2016 Sep 16.

PMID:
27636902
13.

Epidemiological overview, advances in diagnosis, prevention, treatment and management of epithelial ovarian cancer in Mexico.

Gallardo-Rincón D, Espinosa-Romero R, Muñoz WR, Mendoza-Martínez R, Villar-Álvarez SD, Oñate-Ocaña L, Isla-Ortiz D, Márquez-Manríquez JP, Apodaca-Cruz Á, Meneses-García A.

Salud Publica Mex. 2016 Apr;58(2):302-8.

14.

Eradication of cervical cancer in Latin America.

Bosch FX.

Salud Publica Mex. 2016 Apr;58(2):97-100. No abstract available.

15.

Adverse Childhood Experiences and Cervical Cancer Screening.

Alcalá HE, Mitchell E, Keim-Malpass J.

J Womens Health (Larchmt). 2017 Jan;26(1):58-63. doi: 10.1089/jwh.2016.5823. Epub 2016 Aug 8.

PMID:
27500413
16.

Pre-treatment MRI minimum apparent diffusion coefficient value is a potential prognostic imaging biomarker in cervical cancer patients treated with definitive chemoradiation.

Marconi DG, Fregnani JH, Rossini RR, Netto AK, Lucchesi FR, Tsunoda AT, Kamrava M.

BMC Cancer. 2016 Jul 28;16:556. doi: 10.1186/s12885-016-2619-0.

17.

Pretreatment serum lactate dehydrogenase is an independent prognostic factor for patients receiving neoadjuvant chemotherapy for locally advanced cervical cancer.

Li J, Wu MF, Lu HW, Chen Q, Lin ZQ, Wang LJ.

Cancer Med. 2016 Aug;5(8):1863-72. doi: 10.1002/cam4.779. Epub 2016 Jun 28.

18.

Routine Intraoperative Frozen Section Examination to Minimize Bimodal Treatment in Early-Stage Cervical Cancer.

Gubbala PK, Laios A, Wang Z, Dhar S, Pathiraja PJ, Haldar K, Kehoe ST.

Int J Gynecol Cancer. 2016 Jul;26(6):1148-53. doi: 10.1097/IGC.0000000000000738.

PMID:
27258724
19.

Prognostic Use of Pretreatment Hematologic Parameters in Patients Receiving Definitive Chemoradiotherapy for Cervical Cancer.

Onal C, Guler OC, Yildirim BA.

Int J Gynecol Cancer. 2016 Jul;26(6):1169-75. doi: 10.1097/IGC.0000000000000741.

PMID:
27206286
20.

Genotypes distribution of human papillomavirus in cervical samples of Ecuadorian women.

García Muentes GD, García Rodríguez LK, Burgos Galarraga RI, Almeida Carpio F, Ruiz Cabezas JC.

Rev Bras Epidemiol. 2016 Mar;19(1):160-6. doi: 10.1590/1980-5497201600010014.

Supplemental Content

Loading ...
Support Center